Evidence map›Paper›PMID 35123510›Full record

Trial reportJournal of translational medicine2022

Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease.

Philipp Baumann, Francesco Greco, Susanne Wiegert, Sven Wellmann, Giovanni Pellegrini, Vincenzo Cannizzaro

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Philipp BaumannDepartment of Intensive Care Medicine and Neonatology, University Children's Hospital Zurich, Zurich, Switzerland.
Francesco GrecoDepartment of Intensive Care Medicine and Neonatology, University Children's Hospital Zurich, Zurich, Switzerland.
Susanne WiegertDepartment of Intensive Care Medicine and Neonatology, University Children's Hospital Zurich, Zurich, Switzerland.
Sven WellmannZurich Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Giovanni PellegriniLaboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, University of Zurich, Zurich, Switzerland.
Vincenzo CannizzaroZurich Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. vincenzo.cannizzaro@usz.ch.ORCID 0000-0002-5587-160X
University of Zurich · CHUniversity Children's Hospital Zurich · CHUniversity of Basel · CHZurich University of Applied Sciences in Business Administration · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular impairment contributes to increased mortality in preterm infants with chronic lung disease. Macitentan, an endothelin-1 receptor antagonist, has the potential to attenuate pulmonary and cardiovascular remodelling.

methodsIn a prospective randomized placebo-controlled intervention trial, Sprague-Dawley rats were exposed to 0.21 or 1.0 fraction of inspired oxygen (FiO

resultsFiO

conclusionThe endothelin-1 receptor antagonist macitentan attenuated cardiovascular remodelling in an infant rat model for preterm chronic lung disease. This study underscores the potential of macitentan to reduce cardiovascular morbidity in preterm infants with chronic lung disease.

Indexed as

Hypertension, PulmonaryAnimalsHumansInfant, NewbornInfant, PrematureMyocytes, CardiacProspective StudiesPyrimidinesRatsRats, Sprague-DawleySulfonamidesmacitentanPyrimidinesSulfonamidesBronchopulmonary dysplasiaChronic lung diseaseEndothelin receptor blockersInfantsPretermRats

Identifiers

PMID35123510
PMCPMC8818179
OpenAlexW4210524449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.